StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) shareholders

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.41−0.22 (-0.83%)

Close on Nov 17, 2026Market cap $1.70BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
77M of 65M shares
Institutional holders
198
31 new, 28 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
0 buys · 79 sales
Net sold $7.88M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Roderick Wong
Joint filing with RTW Investments, LP (9.90%)
5,940,8669.90%13G (passive) amendmentMar 31, 2026
Abigail P. Johnson
Joint filing with FMR LLC (9.80%)
5,600,9209.80%13G (passive) amendmentDec 31, 2025
Roderick Wong, M.D.
Joint filing with RTW Investments, LP (9.99%)
5,310,0339.99%13G (passive) amendmentDec 31, 2024
FMR LLC
Joint filing with Abigail P. Johnson (7.50%)
4,820,4627.50%13G (passive) amendmentSep 30, 2026
Weston Nichols
Joint filing with Lynx1 Capital Management LP (8.10%)
4,763,6738.10%13G (passive) amendmentMar 31, 2026
Redmile Group, LLC
Joint filing with Jeremy C. Green (6.70%), Redmile Biopharma Investments III, L.P. (5.60%)
4,164,1206.70%13G (passive) amendmentMar 31, 2026
Lynx1 Capital Management LP
Joint filing with Weston Nichols (6.50%)
4,038,4046.50%13G (passive) amendmentJun 30, 2026
Skorpios Trust
Joint filing with Montrago Trustees Ltd (7.20%), Blue Horizon Enterprise Ltd (5.40%)
3,906,1817.20%13D (active) amendmentJun 4, 2025
BlackRock, Inc.3,732,5406.80%13G (passive) amendmentSep 30, 2025
Bvf Inc/Il
Joint filing with Bvf Partners L P/Il (5.60%), Lampert Mark N (5.60%) and 1 more
3,608,9685.60%13G (passive)Sep 23, 2026
Morgan Stanley
Joint filing with Morgan Stanley Capital Services LLC (5.40%)
3,426,7396.50%13G (passive) amendmentDec 31, 2024
Felix J. Baker
Joint filing with Baker Bros. Advisors LP (5.80%), Baker Bros. Advisors (GP) LLC (5.80%) and 1 more
3,336,6975.80%13G (passive) amendmentDec 31, 2025
Wellington Investment Advisors Holdings LLP
Joint filing with Wellington Management Group LLP (5.20%), Wellington Group Holdings LLP (5.20%) and 1 more
3,095,7005.20%13G (passive)Mar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of STOKValueChange% of portfolio
BlackRock, Inc.5,877,3579.11%$192.31M+491,6430.00%
Rtw Investments, LP5,623,5258.72%$184.00M–1.57%
FMR LLC5,313,1008.23%$173.84M−70,5660.01%
Lynx1 Capital Management LP4,038,4046.26%$132.14M−725,26915.27%
Redmile Group, LLC3,945,9206.12%$129.11M−218,2008.67%
Wellington Management Group Llp3,519,3015.45%$115.15M+423,6010.02%
Morgan Stanley3,452,7955.35%$112.98M+29,5150.01%
Baker Bros. Advisors LP3,336,6975.17%$109.18M–0.55%
Toronto Dominion Bank3,173,2584.92%$103.83M–0.12%
State Street Corp2,852,2404.42%$93.33M+575,7280.00%
Price T Rowe Associates Inc /Md/2,661,7394.13%$87.09M+727,5680.01%
Vanguard Capital Management LLC2,586,9374.01%$84.64M+231,3340.00%
Bvf Inc/Il2,547,5573.95%$83.36M–2.13%
T. Rowe Price Investment Management, Inc.2,415,1393.74%$79.02M+2,164,2260.05%
Assenagon Asset Management S.A.2,256,7763.50%$73.84M+1,349,7610.05%
Siren, L.L.C.1,995,3473.09%$65.29M–1.32%
Deerfield Management Company, L.P. (Series C)1,823,5002.83%$59.66M–0.62%
Jupiter Topco LLC1,814,4082.81%$59.36MNew0.02%
Geode Capital Management, LLC1,524,3092.36%$49.88M+202,0490.00%
Dimensional Fund Advisors LP1,013,9111.57%$33.17M+23,9750.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202619877M100.0%31 / 7757 / 2811M4M
Q1 202619871M100.0%44 / 8052 / 2712M5M
Q4 202518367M100.0%46 / 5458 / 138M7M
Q3 202515168M100.0%38 / 4741 / 208M6M
Q2 202513366M100.0%23 / 5133 / 169M7M
Q1 202512663M98.2%24 / 4431 / 278M3M
Q4 202413058M90.3%29 / 3942 / 169M9M
Q3 202411859M90.8%24 / 3836 / 2010M9M
Q2 202411563M97.0%34 / 4822 / 2215M15M
Q1 202410363M96.9%32 / 3626 / 916M2M
Q4 20238149M75.4%7 / 2830 / 218M3M
Q3 20239644M68.1%17 / 2636 / 203M6M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

232 funds held STOK in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of STOKValue% of fundAs of
Vanguard Health Care Fund2,260,5503.50%$65.24M0.17%Jul 31, 2026
Vanguard Total Stock Market Index Fund1,884,6472.92%$61.67M0.00%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1,573,5852.44%$51.49M0.48%Jun 30, 2026
iShares Russell 2000 ETF1,413,7002.19%$46.26M0.06%Jun 30, 2026
Select Biotechnology Portfolio1,293,6942.00%$39.99M0.76%May 31, 2026
T. Rowe Price New Horizons Fund, Inc.729,2011.13%$23.86M0.16%Jun 30, 2026
Vanguard Extended Market Index Fund643,5371.00%$21.06M0.02%Jun 30, 2026
Select Health Care Portfolio628,0000.97%$19.41M0.34%May 31, 2026
Fidelity Small Cap Index Fund602,3400.93%$17.38M0.05%Jul 31, 2026
Fidelity Small Cap Growth Fund520,8250.81%$15.03M0.17%Jul 31, 2026
iShares Russell 2000 Growth ETF508,4160.79%$16.64M0.11%Jun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund495,8870.77%$16.23M0.17%Jun 30, 2026
BlackRock Health Sciences Opportunities Portfolio473,1520.73%$14.63M0.25%May 29, 2026
Fidelity Stock Selector Small Cap Fund435,3000.67%$12.56M0.17%Jul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.418,9340.65%$13.71M0.11%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Ian F. SmithChief Executive Officer, Director––Feb 19, 2026
Barry TichoCHIEF MEDICAL OFFICER11,8640.02%Nov 4, 2026
Jonathan AllanGENERAL COUNSEL & CORP SEC20,5980.03%Oct 2, 2026
Thomas McCauleyChief Scientific Officer––Jul 17, 2026
Jason HoittChief Patient Officer10,2760.02%Mar 19, 2026
Thomas LeggettChief Financial Officer10,3810.02%Mar 19, 2026
Alexander CumboDirector––Sep 25, 2026
Edward M. Kaye MDDirector125,1940.19%Aug 18, 2026
Seth Loring HarrisonDirector17,161,71326.60%Jul 17, 2026
Arthur TzianabosDirector35,6940.06%Jun 5, 2026
Julie SmithDirector0–Jun 5, 2026
Jennifer BursteinDirector0–Jun 5, 2026
Adrian R. KrainerDirector283,3020.44%Jun 5, 2026
Arthur A. LevinDirector22,2160.03%Jun 5, 2026
Clare KahnDirector––Apr 7, 2026
Garry E. MenzelDirector0–Jun 4, 2025
Trustees Ltd Montrago10% owner14,443,68122.38%Jun 6, 2025
Horizon Enterprise Ltd Blue10% owner6,906,18110.70%Jun 6, 2025
International Ltd Ezbon10% owner––Jun 6, 2025
Trust Skorpios10% owner3,906,1816.05%Jun 6, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Barry Ticho
CHIEF MEDICAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−200$26.99$5.40K11,864
Barry Ticho
CHIEF MEDICAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−6,995$26.38$184.51K12,064
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Oct 2, 2026Sale(10b5-1 plan)−627$26.33$16.51K20,598
Barry Ticho
CHIEF MEDICAL OFFICER
Oct 1, 2026Sale(10b5-1 plan)−1,051$26.16$27.49K19,059
Barry Ticho
CHIEF MEDICAL OFFICER
Sep 1, 2026Sale(10b5-1 plan)−3,945$30.51$120.36K21,710
Barry Ticho
CHIEF MEDICAL OFFICER
Sep 1, 2026Sale(10b5-1 plan)−1,600$31.06$49.70K20,110
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Aug 18, 2026Sale−2,716$32.01$86.94K21,370
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Aug 18, 2026Sale−145$32.47$4.71K21,225
Barry Ticho
CHIEF MEDICAL OFFICER
Aug 18, 2026Sale−4,525$32.01$144.85K25,897
Barry Ticho
CHIEF MEDICAL OFFICER
Aug 18, 2026Sale−242$32.47$7.86K25,655
Edward M. Kaye MD
Director
Aug 18, 2026Sale−11,930$32.01$381.88K125,194
Edward M. Kaye MD
Director
Aug 18, 2026Sale−637$32.47$20.68K124,557
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Aug 14, 2026Option exercise+6,000––24,086
Barry Ticho
CHIEF MEDICAL OFFICER
Aug 14, 2026Option exercise+10,000––30,422
Edward M. Kaye MD
Director
Aug 14, 2026Option exercise+26,250––137,124
Barry Ticho
CHIEF MEDICAL OFFICER
Aug 3, 2026Sale(10b5-1 plan)−1,269$29.45$37.37K20,422
Barry Ticho
CHIEF MEDICAL OFFICER
Aug 3, 2026Sale(10b5-1 plan)−5,907$28.95$171.01K21,691
Barry Ticho
CHIEF MEDICAL OFFICER
Jul 1, 2026Sale(10b5-1 plan)−6,728$32.62$219.47K28,098
Barry Ticho
CHIEF MEDICAL OFFICER
Jul 1, 2026Sale(10b5-1 plan)−500$33.27$16.64K27,598
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Jun 16, 2026Sale(10b5-1 plan)−1,457$29.95$43.64K18,086
Barry Ticho
CHIEF MEDICAL OFFICER
Jun 1, 2026Sale(10b5-1 plan)−1,795$30.58$54.89K34,826
Barry Ticho
CHIEF MEDICAL OFFICER
May 1, 2026Sale(10b5-1 plan)−2,243$32.79$73.55K36,621
Barry Ticho
CHIEF MEDICAL OFFICER
Apr 1, 2026Sale(10b5-1 plan)−1,838$32.66$60.03K38,864
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Mar 20, 2026Sale(10b5-1 plan)−601$34.41$20.68K19,543
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Mar 20, 2026Sale(10b5-1 plan)−8,692$33.64$292.40K20,144
Barry Ticho
CHIEF MEDICAL OFFICER
Mar 19, 2026Option exercise+1,365$2.19$2.99K42,163
Barry Ticho
CHIEF MEDICAL OFFICER
Mar 19, 2026Sale(10b5-1 plan)−1,461$29.99$43.82K40,702
Thomas Leggett
Chief Financial Officer
Mar 18, 2026Sale−2,173$31.28$67.97K10,381
Thomas Leggett
Chief Financial Officer
Mar 18, 2026Sale−172$31.79$5.47K10,209
Thomas Leggett
Chief Financial Officer
Mar 18, 2026Sale−37$32.85$1.22K10,172
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Mar 18, 2026Sale−334$31.79$10.62K28,908
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Mar 18, 2026Sale−72$32.85$2.37K28,836
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Mar 18, 2026Sale−4,222$31.28$132.06K29,242
Barry Ticho
CHIEF MEDICAL OFFICER
Mar 18, 2026Sale(10b5-1 plan)−483$31.79$15.35K40,901
Barry Ticho
CHIEF MEDICAL OFFICER
Mar 18, 2026Sale(10b5-1 plan)−103$32.85$3.38K40,798
Barry Ticho
CHIEF MEDICAL OFFICER
Mar 18, 2026Sale(10b5-1 plan)−6,100$31.28$190.81K41,384
Jason Hoitt
Chief Patient Officer
Mar 18, 2026Sale−30$32.85$98610,276
Jason Hoitt
Chief Patient Officer
Mar 18, 2026Sale−1,762$31.28$55.12K10,445
Jason Hoitt
Chief Patient Officer
Mar 18, 2026Sale−139$31.79$4.42K10,306
Thomas Leggett
Chief Financial Officer
Mar 17, 2026Sale−1,274$32.74$41.71K13,476
Thomas Leggett
Chief Financial Officer
Mar 17, 2026Sale−922$33.38$30.78K12,554
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Mar 17, 2026Sale−1,791$33.38$59.78K33,464
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Mar 17, 2026Sale−2,476$32.74$81.06K35,255
Barry Ticho
CHIEF MEDICAL OFFICER
Mar 17, 2026Sale(10b5-1 plan)−2,587$33.38$86.35K47,484
Barry Ticho
CHIEF MEDICAL OFFICER
Mar 17, 2026Sale(10b5-1 plan)−3,577$32.74$117.11K50,071
Jason Hoitt
Chief Patient Officer
Mar 17, 2026Sale−1,033$32.74$33.82K12,955
Jason Hoitt
Chief Patient Officer
Mar 17, 2026Sale−748$33.38$24.97K12,207
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Mar 15, 2026Option exercise+7,475––19,731
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Mar 15, 2026Option exercise+12,000––37,731
Jonathan Allan
GENERAL COUNSEL & CORP SEC
Mar 15, 2026Option exercise+6,000––25,731
Edward M. Kaye MD
Director
Mar 15, 2026Option exercise+26,250––110,874
Edward M. Kaye MD
Director
Mar 15, 2026Option exercise+35,500––84,624
Barry Ticho
CHIEF MEDICAL OFFICER
Mar 15, 2026Option exercise+10,000––42,898
Barry Ticho
CHIEF MEDICAL OFFICER
Mar 15, 2026Option exercise+13,100––32,898
Barry Ticho
CHIEF MEDICAL OFFICER
Mar 15, 2026Option exercise+10,750––53,648
Thomas Leggett
Chief Financial Officer
Mar 15, 2026Option exercise+14,750––14,750
Jason Hoitt
Chief Patient Officer
Mar 15, 2026Option exercise+10,000––13,988
Arthur A. Levin
Director
Mar 13, 2026Sale(10b5-1 plan)−605$36.80$22.26K4,237
Adrian R. Krainer
Director
Mar 10, 2026Sale(10b5-1 plan)−33,243$39.74$1.32M283,302
Arthur Tzianabos
Interim Executive Chair, Director
Mar 10, 2026Option exercise+3,955$8.33$32.95K35,694

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
28.45%
11M shares short
Days to cover
6.8
At 2M shares a day
Change since last report
+4.5%
From 10M shares
Short volume, 20 days
62.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Stoke Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,076 shares on Sep 17, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Edward M. Kaye MD
Former Affiliate
Oct 21, 20261,496,042$38.42MOct 21, 2026Exercise of Options Under a Registered Plan
Jonathan Allan
Officer
Oct 2, 2026627$16.31KOct 2, 2026Restricted Stock Units
Baruch Ticho
Officer
Aug 3, 202620,967$605.11KAug 3, 2026Restricted Stock Units
Baruch S. Ticho
Officer
Jul 1, 20267,228$236.50KJul 1, 2026Restricted Stock Units
Jonathan Allan
Officer
Jun 16, 20261,457$43.71KJun 16, 2026Restricted Stock Units
Baruch S. Ticho
Officer
May 1, 20264,038$132.12KMay 1, 2026Restricted Stock Units
Baruch S. Ticho
Officer
Apr 1, 20261,838$59.85KApr 1, 2026Restricted Stock Units
Jonathan Allan
Officer
Mar 20, 20269,293$308.43KMar 20, 2026Restricted Stock Units
Baruch S. Ticho
Officer
Mar 19, 20261,461$45.32KMar 19, 2026Exercise of Stock Options
Arthur A. Levin
Director
Mar 13, 2026605$22.07KMar 13, 2026Restricted Stock Units
Arthur Tzianabos
Director
Mar 10, 202690,508$3.47MMar 10, 2026Exercise of Stock Options
Adrian R. Krainer
Director
Mar 2, 202640,472$1.47MMar 2, 2026Founders Shares
Edward M. Kaye MD
Director
Dec 8, 202513,430$414.58KDec 8, 2025Performance Stock Units
Jonathan Allan
Officer
Dec 8, 20253,978$122.80KDec 8, 2025Performance Stock Units
Jonathan Allan
Officer
Dec 5, 20257,781$241.60KDec 5, 2025Restricted Stock Units

See a number that looks wrong?